Overview

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study comparing the efficacy of nebivolol and atenolol at improving small artery elasticity and reducing cardiovascular disease risk in subjects with early vascular disease. Approximately 75 subjects with borderline/elevated blood pressures and impaired endothelial function, as measured by arterial elasticity scores, will be recruited and assigned to treatment groups using a block randomization scheme. Patients will be randomly allocated to nebivolol, atenolol or placebo, and then followed for 9 months.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota
University of Minnesota - Clinical and Translational Science Institute
Collaborator:
Forest Laboratories
Treatments:
Atenolol
Nebivolol